Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]

Core Insights - SOPHiA GENETICS announced an expansion of its collaboration with AstraZeneca to enhance the global deployment of MSK-ACCESS® powered with SOPHiA DDM™, extending its reach to 30 clinical institutions in 2025 [1][3] Group 1: Collaboration and Expansion - The collaboration aims to accelerate the deployment of innovative liquid biopsy testing, which detects actionable genomic alterations from a single blood draw [2][3] - The expanded rollout will contribute to AstraZeneca's global real-world evidence initiatives and validate the clinical impact of decentralized liquid biopsy testing [3][4] Group 2: Technology and Performance - MSK-ACCESS® powered with SOPHiA DDM™ utilizes advanced algorithms to analyze circulating tumor DNA (ctDNA), supporting real-time cancer monitoring and treatment selection [2][4] - Data presented at AACR demonstrated the consistent accuracy and precision of the decentralized test across various laboratory settings, addressing historical site-to-site discordance issues [4][5] Group 3: Strategic Vision - The collaboration reflects a significant step toward scaling next-generation oncology diagnostics globally, with a shared ambition to enhance accessibility and impact of liquid biopsy technologies [5]